---
title: "Relmada Therapeutics Joins Russell 2000 Index And Russell 3000 Index"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291138762.md"
description: "Relmada Therapeutics, Inc. (NASDAQ:RLMD, “Relmada” or the “Company”))), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that the Company joined the Russell 2000® Index and the Russell 3000® Index effective after the U.S. market closed on June 26, 2026, as part of the Russell Indexes reconstitution."
datetime: "2026-06-29T11:08:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291138762.md)
  - [en](https://longbridge.com/en/news/291138762.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291138762.md)
generator: "portal-rs"
---

# Relmada Therapeutics Joins Russell 2000 Index And Russell 3000 Index

Relmada Therapeutics, Inc. (NASDAQ:RLMD, “Relmada” or the “Company”))), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that the Company joined the Russell 2000® Index and the Russell 3000® Index effective after the U.S. market closed on June 26, 2026, as part of the Russell Indexes reconstitution.

### Related Stocks

- [RLMD.US](https://longbridge.com/en/quote/RLMD.US.md)

## Related News & Research

- [Relmada publishes investor presentation highlighting NDV-01 program for non-muscle invasive bladder cancer](https://longbridge.com/en/news/295148682.md)
- [Relmada Q2 FY26 net loss widens to $12.9 million; R&D expense rises to $8.4 million](https://longbridge.com/en/news/295140125.md)
- [Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call](https://longbridge.com/en/news/290233507.md)
- [Analyst Reaffirms Buy Rating on Unicycive, Maintaining 12-Month Price Target at $30 After FDA Procedural Setback](https://longbridge.com/en/news/296255704.md)
- [ADAR1 Capital Management LLC Grows Stock Position in Relmada Therapeutics, Inc. $RLMD](https://longbridge.com/en/news/294166619.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**